Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
Would you use neoadjuvant CDK4/6 inhibitor and AI in HR+ breast cancer based upon the randomized phase II CORALLEEN trial?
https://www.ncbi.nlm.nih.gov/pubmed/31838010
Answer from: Medical Oncologist at Academic Institution
I would not use CDK inhibitors in the neoadjuvant setting.
Sign in or Register to read more
6750
Related Questions
What adjuvant treatment approach would you choose for a premenopausal woman with lymph node positive poorly differentiated metaplastic breast cancer that is ER low+, PR+, HER2 negative?
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?
Is there a role of adding hormonal therapy to fam-trastuzumab deruxtecan in patients with metastatic ER/PR+ HER2 low breast cancer after progressing on aromatase inhibitor and CDK4/6i?
Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
What is your cut off on ER percent positivity to treat breast cancer as functional triple negative cancer?
Would you offer adjuvant Abemciclib to ER positive HER2 negative with 1 LN positive, Ki-67 >20%, and low Oncotype?
How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?
What is your preferred first line therapy for metastatic HR+ inflammatory breast cancer?